Maribavir
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Maribavir
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Maribavir 200 mg tablet for treating post-transplant cytomegalovirus infection or disease in adults who are refractory (with or without genotypic resistance) or intolerant to prior antiviral therapy.
Funding status
[R] Maribavir 200 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.
[R] Maribavir should be used in line with the additional clinical criteria listed in the Annex.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Oral
* Clinical information is available for this product.